In conclusion, we here show the potential of the integrative analysis of RNA sequencing and WGS and demonstrate that within the subgroup of ER-positive/HER2-negative breast cancers there are substantial differences in ESR1 expression and its target genes. The gene discussed is ESR1; the disease is breast carcinoma.